UPDATE: Morgan Stanley Initiates Coverage On IMS Health On Attractive End Market, Healthy Valuation

In a report published Wednesday, Morgan Stanley analyst Suzanne E. Stein initiated coverage on

with an Equal-Weight rating and $26.00 price target. In the report, Morgan Stanley noted, “IMS is an attractive way for investors to participate in the growing healthcare analytics end-market. We see valuation as fair, given our outlook for mid-single-digit top-line growth, modest margin expansion, and strong free cash flow.” IMS Health closed on Tuesday at $25.21.